Last updated: March 9, 2026
What is NDC 69238-2676?
NDC 69238-2676 refers to Moxetumomab pasudotox-tdfk (Leukocyte), a targeted therapy approved by the FDA for the treatment of relapsed or refractory hairy cell leukemia (HCL).
Market Landscape
Indications and Patient Population
- Indication: Treatment of HCL patients after at least two prior systemic therapies.
- Patient Population: Estimated 600-800 annual U.S. patients, based on disease prevalence data.
Competitive Environment
- Current therapies: Cladribine, pentostatin, and relapsed chemotherapy.
- Unique selling point: First FDA-approved targeted immunotoxin for HCL.
Market Potential
| Parameter |
Data |
| U.S. HCL patient prevalence |
~600-800 (per year) |
| Estimated market penetration (year 1) |
10-20% |
| Price per vial |
~$12,000 - $15,000 |
| Dosing regimen |
0.04 mg/kg IV on days 1, 3, 5, 8, 10, 12 |
| Average treatment course |
4-6 doses |
| Gross sales potential (year 1) |
$36 million (at 10% penetration, $15,000/vial) |
Market Entry Considerations
- Market exclusivity and off-label competition influence pricing and volume.
- Insurance coverage and prior authorization protocols can affect uptake.
Price Trends and Projections
Current Pricing
- Current list price: approximately $15,000 per vial.
- Cost per treatment course: varies between $60,000 and $90,000 depending on patient weight and number of doses.
Short-term Price Outlook (Next 1-2 years)
- Slight downward pressure expected due to payer negotiations and bulk discounts.
- Potential price stabilization at $14,000–$15,000 per vial for initial launch years.
Long-term Price Projections (3-5 years)
- Prices may decline 10-15% driven by increased competition or biosimilar entrants (if applicable).
- Specialty drug discounts and patient assistance programs could further reduce effective price.
Revenue and Market Share Forecasts
| Year |
Estimated Patients |
Market Penetration |
Vial Sales |
Revenue (USD) |
| 2023 |
600 |
10% |
3600 vials |
$54 million |
| 2024 |
800 |
15% |
12,000 vials |
$180 million |
| 2025 |
800 |
20% |
16,000 vials |
$240 million |
Note: These estimates assume consistent pricing and no major market disruptions.
Regulatory and Pricing Policy Impacts
- U.S. Medicare Part B reimbursement policies could influence net prices.
- Potential for Medicaid and commercial payer negotiations to lower prices over time.
- The FDA’s policy on biosimilars could influence future price dynamics.
Key Takeaways
- NDC 69238-2676 addresses a niche but significant unmet need in HCL.
- The market is small but represents a lucrative segment for early adopters.
- Initial pricing is around $15,000 per vial, with potential for modest reductions over the next few years.
- Revenue projections range from $54 million in 2023 to over $240 million by 2025, assuming increased uptake.
- Competitive pressures and biosimilar developments could influence long-term pricing.
FAQs
Q1: What factors most influence the drug’s pricing stability?
A: Reimbursement negotiations, market penetration, competition, and payer policies.
Q2: How does the treatment regimen affect revenue projections?
A: Longer or more frequent dosing increases vial sales, raising revenue.
Q3: Are biosimilars likely for this drug?
A: Biosimilars for immunotoxins are unlikely soon; regulatory and patent protections limit competitors.
Q4: How significant is the impact of insurance coverage?
A: Critical; prior authorization and formulary inclusion determine market access and revenue.
Q5: What are the primary risks to revenue forecasts?
A: Pricing pressures, regulatory changes, adverse safety data, or alternative therapies gaining approval.
References
- Food and Drug Administration. (2018). FDA approves leukocyte immunotoxin for hairy cell leukemia. Retrieved from [FDA website].
- IQVIA. (2022). U.S. Oncology Market Trends.
- Centers for Disease Control and Prevention. (2020). Hematologic Malignancies Prevalence Data.
- EvaluatePharma. (2023). Oncology drug market forecasts.
- CMS.gov. (2023). Medicare Part B reimbursement policies.
Note: The data provided is based on industry estimates, publicly available data, and market models as of early 2023.
